Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Medtronic
McKinsey
Moodys
Merck

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

HUMIRA Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Litigation for HUMIRA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Coherus Biosciences, Inc. v. Amgen Inc.2019-01-24
ABBVIE INC. v. SANDOZ INC.2018-08-10
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06

See all HUMIRA litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
Sandoz Inc.2017-11-06
Sandoz Inc.2017-10-02

See all HUMIRA litigation

Pharmacology for HUMIRA

US Patents for HUMIRA

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Children\'s Hospital Medical Center (Cincinnati, OH) Westfaelische Wilhelms-Universitaet Muenster (Muenster, DE) 2033-05-14 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial GALAPAGOS NV (Mechelen, BE) 2031-04-28 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial AbbVie Inc. (North Chicago, IL) 2031-09-22 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial BIONANOPLUS, S.L. (Noain-Navarra, ES) 2032-02-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for HUMIRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15C0029 France   Start Trial PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2015/020 Ireland   Start Trial PRODUCT NAME: IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/945 20141021
LUC00050 Luxembourg   Start Trial PRODUCT NAME: SARILUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (KEVZARA); AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
CR 2017 00061 Denmark   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
92692 Luxembourg   Start Trial PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.